Ellen Geerdens
Overview
Explore the profile of Ellen Geerdens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
1080
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Froyen G, Volders P, Geerdens E, Berden S, Van der Meulen J, De Cock A, et al.
Mol Oncol
. 2025 Jan;
PMID: 39887903
Somatic multigene analysis by next-generation sequencing (NGS) is routinely integrated in medical oncology for clinical decision-making. However, with the fast-growing number of recommended and required genes as well as pan-cancer...
2.
Delsupehe L, Steelandt T, Lemahieu J, Volders P, Geerdens E, Berden S, et al.
Virchows Arch
. 2023 Sep;
485(2):269-279.
PMID: 37731064
In addition to morphologic analysis, molecular diagnostic work up of Spitz tumours is often of great value for their accurate diagnosis/classification. Nowadays, next-generation sequencing (NGS) is the predominant screening method...
3.
Cuppens K, Baas P, Geerdens E, Cruys B, Froyen G, Decoster L, et al.
Lung Cancer
. 2022 Jun;
170:1-10.
PMID: 35689896
Objectives: Immune checkpoint inhibitors (ICIs) improved outcomes in non-small cell lung cancer (NSCLC) patients. We report the predictive utility of human leukocyte antigen class I (HLA-I) diversity and tumor mutational...
4.
Froyen G, Geerdens E, Berden S, Cruys B, Maes B
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626061
The use of targeted Next Generation Sequencing (NGS) for the diagnostic screening of somatic variants in solid tumor samples has proven its high clinical value. Because of the large number...
5.
Oben B, Cosemans C, Geerdens E, Linsen L, Vanhees K, Maes B, et al.
Cancers (Basel)
. 2022 Feb;
14(4).
PMID: 35205782
Multiple myeloma (MM), or Kahler's disease, is an incurable plasma cell (PC) cancer in the bone marrow (BM). This malignancy is preceded by one or more asymptomatic precursor conditions, monoclonal...
6.
Van Thillo Q, De Bie J, Seneviratne J, Demeyer S, Omari S, Balachandran A, et al.
Nat Commun
. 2021 Jul;
12(1):4164.
PMID: 34230493
Spi-1 Proto-Oncogene (SPI1) fusion genes are recurrently found in T-cell acute lymphoblastic leukemia (T-ALL) cases but are insufficient to drive leukemogenesis. Here we show that SPI1 fusions in combination with...
7.
Oben B, Froyen G, Maclachlan K, Leongamornlert D, Abascal F, Zheng-Lin B, et al.
Nat Commun
. 2021 Mar;
12(1):1861.
PMID: 33767199
Multiple myeloma (MM) is consistently preceded by precursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SMM). We interrogate the whole genome sequence (WGS) profile...
8.
Broux M, Prieto C, Demeyer S, Vanden Bempt M, Alberti-Servera L, Lodewijckx I, et al.
Blood
. 2019 Sep;
134(16):1323-1336.
PMID: 31492675
The polycomb repressive complex 2, with core components EZH2, SUZ12, and EED, is responsible for writing histone 3 lysine 27 trimethylation histone marks associated with gene repression. Analysis of sequence...
9.
Vanden Bempt M, Demeyer S, Broux M, De Bie J, Bornschein S, Mentens N, et al.
Cancer Cell
. 2018 Aug;
34(2):271-285.e7.
PMID: 30107177
The NUP214-ABL1 fusion is a constitutively activated tyrosine kinase that is significantly associated with overexpression of the TLX1 and TLX3 transcription factors in T cell acute lymphoblastic leukemia (T-ALL). Here...
10.
De Bie J, Demeyer S, Alberti-Servera L, Geerdens E, Segers H, Broux M, et al.
Leukemia
. 2018 May;
32(6):1358-1369.
PMID: 29740158
Next-generation sequencing has provided a detailed overview of the various genomic lesions implicated in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL). Typically, 10-20 protein-altering lesions are found in T-ALL...